Hospital
Fresno Community Hospital and Medical Center
Fresno Community Hospital and Medical Center was paid $14.51M by Medicaid between Jan 2018 and Dec 2024, across 335 billing codes. Its largest line is 0450, Emergency room services — 17% of everything it billed.
33Billing provider infoFRESNO COMMUNITY HOSPITAL AND MEDICAL CENTER
CLOVIS, CA 93611
CLOVIS, CA 93611
33aNPI1316027709assigned 10/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.51M
24GClaims1,712,850
24DCodes billed335
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#154 of 410
Median peer was paid$6.90M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 199,600 | $2.19M | |
| 2019 | 229,264 | $2.02M | |
| 2020 | 198,477 | $1.23M | |
| 2021 | 229,816 | $1.65M | |
| 2022 | 259,105 | $1.96M | |
| 2023 | 317,004 | $2.73M | |
| 2024incomplete | 279,584 | $2.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 17% | 130,898 | 117,616 | $2.46M |
| J3490 | Unclassified drugs | 12% | 83,378 | 35,660 | $1.79M |
| 80048 | Basic metabolic panel (calcium, ionized) | 12% | 92,545 | 86,561 | $1.70M |
| 99199 | Unlisted special service, procedure or report | 9.5% | 21,065 | 20,196 | $1.38M |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 6.5% | 8,439 | 4,905 | $937K |
| J9271 | Injection, pembrolizumab, 1 mg | 3.5% | 1,010 | 784 | $510K |
| Z7502 | 3.2% | 12,468 | 12,279 | $466K | |
| Z9725 | 2.7% | 9,132 | 9,103 | $393K | |
| 77386 | 2.1% | 5,581 | 529 | $310K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 26,570 | 22,019 | $309K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 20,793 | 19,450 | $289K |
| 80047 | 2.0% | 15,858 | 14,291 | $286K |
323 more codes
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 1.4% | 1,657 | $206K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.4% | 17,523 | $199K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 154,951 | $190K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.1% | 26,424 | $154K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,006 | $133K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 805 | $115K |
| 80053 | Comprehensive metabolic panel | <1% | 43,502 | $112K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12,783 | $106K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 28,542 | $99K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 50,558 | $96K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 11,999 | $86K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,027 | $86K |
| 0360 | <1% | 3,959 | $78K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,211 | $76K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 39,317 | $73K |
| 96367 | <1% | 8,842 | $63K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,469 | $59K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,370 | $56K |
| 0761 | <1% | 4,161 | $56K | |
| 81001 | <1% | 54,314 | $49K | |
| Z7610 | <1% | 5,998 | $44K | |
| 99283 | Emergency room visit (moderate) | <1% | 2,947 | $43K |
| 81025 | <1% | 5,053 | $42K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,077 | $38K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,029 | $32K |
| 96379 | <1% | 611 | $31K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 878 | $31K |
| 0160 | <1% | 2,474 | $31K | |
| 77300 | <1% | 693 | $31K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,209 | $30K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 7,042 | $29K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 6,218 | $29K |
| 86900 | <1% | 7,339 | $29K | |
| 80076 | <1% | 53,338 | $26K | |
| 77336 | <1% | 3,156 | $25K | |
| 59025 | Fetal non-stress test | <1% | 9,881 | $24K |
| 77334 | <1% | 964 | $23K | |
| 84702 | <1% | 23,595 | $22K | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 285 | $21K |
| 84484 | <1% | 23,975 | $21K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,189 | $20K |
| 83690 | <1% | 34,768 | $20K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 594 | $20K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 2,419 | $20K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 6,135 | $19K |
| 96415 | <1% | 4,023 | $19K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,638 | $19K |
| 96417 | <1% | 3,343 | $18K | |
| 83615 | <1% | 12,227 | $18K | |
| 0270 | <1% | 97,240 | $18K | |
| 93975 | <1% | 1,597 | $18K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 871 | $17K |
| 77412 | <1% | 3,116 | $17K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 91 | $17K |
| 86850 | <1% | 4,888 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,152 | $16K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,805 | $15K |
| 73564 | <1% | 2,956 | $14K | |
| 0710 | <1% | 1,985 | $13K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,195 | $13K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 16,205 | $13K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,277 | $13K |
| 73610 | <1% | 2,635 | $13K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,905 | $13K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 977 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,406 | $12K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,117 | $11K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 555 | $11K |
| 0324 | <1% | 337 | $11K | |
| 71250 | <1% | 409 | $11K | |
| 73130 | <1% | 2,238 | $11K | |
| 97139 | <1% | 3,454 | $11K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 311 | $11K |
| 96416 | <1% | 1,933 | $10K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,796 | $10K |
| 77080 | <1% | 663 | $10K | |
| 87088 | <1% | 9,988 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,267 | $10K |
| 0250 | <1% | 1,666 | $10K | |
| 73630 | <1% | 3,150 | $10K | |
| 76642 | <1% | 3,297 | $10K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 10,174 | $9K |
| 76830 | Ultrasound, transvaginal | <1% | 4,804 | $9K |
| 99284 | Emergency room visit (serious) | <1% | 1,169 | $9K |
| 82728 | <1% | 5,979 | $8K | |
| 73110 | <1% | 1,661 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,900 | $7K |
| 96411 | <1% | 2,253 | $7K | |
| 73030 | <1% | 2,537 | $7K | |
| 97750 | <1% | 1,173 | $7K | |
| 93971 | <1% | 2,261 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,374 | $7K |
| 86923 | <1% | 1,145 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,599 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,794 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,849 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,832 | $6K |
| 96377 | <1% | 673 | $6K | |
| 87632 | <1% | 1,206 | $6K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,603 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,032 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,603 | $6K |
| 0750 | <1% | 27 | $6K | |
| 0760 | <1% | 8,735 | $6K | |
| 87503 | <1% | 6,937 | $6K | |
| 72100 | <1% | 1,654 | $6K | |
| 87081 | <1% | 2,544 | $6K | |
| 84466 | <1% | 5,771 | $6K | |
| 83880 | <1% | 8,067 | $6K | |
| 76770 | <1% | 938 | $6K | |
| 84550 | <1% | 6,331 | $6K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 3,525 | $6K |
| 82746 | <1% | 4,422 | $5K | |
| 77290 | <1% | 191 | $5K | |
| 83735 | <1% | 5,236 | $5K | |
| 85045 | <1% | 5,746 | $4K | |
| 76801 | <1% | 3,577 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,969 | $4K |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 47 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 858 | $4K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 421 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 371 | $4K |
| 87077 | <1% | 3,677 | $3K | |
| 70491 | <1% | 292 | $3K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 379 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,331 | $3K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 475 | $3K |
| 82784 | <1% | 1,380 | $3K | |
| 84703 | <1% | 8,840 | $3K | |
| 85730 | <1% | 2,719 | $3K | |
| 71020 | <1% | 612 | $3K | |
| 73080 | <1% | 747 | $3K | |
| 83540 | <1% | 5,746 | $3K | |
| 82378 | <1% | 1,692 | $3K | |
| 85610 | <1% | 6,984 | $3K | |
| 85379 | <1% | 5,802 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,016 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,025 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,438 | $3K |
| 87210 | <1% | 4,408 | $3K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 2,537 | $2K |
| 72050 | <1% | 365 | $2K | |
| 77295 | <1% | 75 | $2K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 962 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 578 | $2K |
| 82607 | <1% | 4,172 | $2K | |
| 83883 | <1% | 1,181 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,977 | $2K |
| 84439 | <1% | 3,072 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 423 | $2K |
| 86901 | <1% | 7,277 | $2K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 2,240 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,232 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,609 | $2K |
| 87040 | <1% | 2,656 | $2K | |
| 76870 | <1% | 295 | $2K | |
| 85027 | <1% | 2,451 | $2K | |
| 82731 | <1% | 852 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,025 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 758 | $2K |
| 74018 | <1% | 521 | $1K | |
| 86780 | <1% | 1,327 | $1K | |
| 83605 | <1% | 4,476 | $1K | |
| 73502 | <1% | 708 | $1K | |
| 77338 | <1% | 40 | $1K | |
| 73590 | <1% | 801 | $1K | |
| 82565 | <1% | 2,457 | $1K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 536 | $1K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 3,715 | $1K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 53 | $1K |
| 72131 | <1% | 371 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,569 | $1K |
| 84100 | <1% | 2,430 | $1K | |
| 87186 | <1% | 3,304 | $1K | |
| 0301 | <1% | 109 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 134 | $1K |
| 74178 | <1% | 12 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,806 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,214 | $1K |
| 87430 | <1% | 2,784 | $1K | |
| 93970 | <1% | 319 | $1K | |
| 96549 | <1% | 1,077 | $1K | |
| 0403 | <1% | 17 | $1K | |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | <1% | 16 | $1K |
| 90715 | <1% | 1,753 | $1K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 41 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,150 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,991 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,642 | $1K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 52 | $925.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 35 | $907.16 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 864 | $901.84 |
| 72141 | <1% | 50 | $878.71 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 248 | $871.25 |
| 86334 | <1% | 965 | $860.00 | |
| 88342 | <1% | 193 | $817.77 | |
| 70486 | <1% | 127 | $814.49 | |
| 96401 | <1% | 356 | $807.57 | |
| 99285 | Emergency room visit (most serious) | <1% | 256 | $758.77 |
| 80061 | Lipid panel | <1% | 576 | $755.56 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 569 | $711.87 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 61 | $693.71 |
| 77280 | <1% | 102 | $668.41 | |
| 94644 | <1% | 212 | $659.51 | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 36 | $652.64 |
| 94664 | <1% | 1,153 | $648.52 | |
| 82105 | <1% | 40 | $592.25 | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 1,240 | $576.70 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,198 | $556.77 |
| A4217 | Sterile water/saline, 500 ml | <1% | 97 | $548.03 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 397 | $534.69 |
| 84165 | <1% | 1,072 | $526.95 | |
| 86308 | <1% | 393 | $505.63 | |
| 99152 | <1% | 85 | $496.37 | |
| 82247 | <1% | 522 | $494.97 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 15 | $475.57 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,573 | $457.82 |
| 0320 | <1% | 17 | $442.85 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 304 | $438.44 |
| 86140 | <1% | 1,494 | $418.52 | |
| 82570 | <1% | 1,142 | $398.16 | |
| 80074 | <1% | 76 | $396.70 | |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 115 | $370.01 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 71 | $364.33 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 78 | $342.01 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 263 | $336.62 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,313 | $331.01 |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | <1% | 44 | $320.69 |
| 86304 | <1% | 167 | $318.50 | |
| 11043 | <1% | 21 | $313.88 | |
| 96402 | <1% | 700 | $311.97 | |
| 83010 | <1% | 155 | $310.72 | |
| 84460 | <1% | 496 | $299.12 | |
| 84450 | <1% | 481 | $285.23 | |
| 85651 | <1% | 1,399 | $283.15 | |
| 73562 | <1% | 36 | $265.12 | |
| 90686 | <1% | 138 | $255.55 | |
| 96376 | <1% | 957 | $253.91 | |
| 96368 | <1% | 208 | $249.69 | |
| 87506 | <1% | 194 | $240.26 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,015 | $235.70 |
| 96523 | <1% | 34 | $223.17 | |
| 76641 | <1% | 184 | $207.52 | |
| 84156 | <1% | 1,088 | $203.42 | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 177 | $198.27 |
| 70498 | <1% | 27 | $190.93 | |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 27 | $174.38 |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 72 | $171.96 |
| 73090 | <1% | 265 | $170.47 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 155 | $161.26 |
| 90744 | <1% | 1,110 | $128.08 | |
| 82550 | <1% | 576 | $126.91 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 15 | $122.72 |
| J1815 | Injection, insulin, per 5 units | <1% | 676 | $111.66 |
| 82140 | <1% | 431 | $100.37 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 80 | $88.75 |
| 73060 | <1% | 27 | $85.79 | |
| 87070 | <1% | 193 | $80.08 | |
| 87075 | <1% | 134 | $74.86 | |
| 95816 | <1% | 13 | $72.56 | |
| 87205 | <1% | 317 | $70.59 | |
| 71010 | <1% | 59 | $70.58 | |
| 85384 | <1% | 46 | $68.29 | |
| 73140 | <1% | 24 | $67.32 | |
| 84155 | <1% | 655 | $65.86 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 84 | $65.28 |
| 84520 | <1% | 186 | $64.15 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 78 | $63.35 |
| 87340 | <1% | 26 | $57.72 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,463 | $50.82 |
| 74000 | <1% | 24 | $48.39 | |
| 86300 | <1% | 137 | $46.92 | |
| 97163 | <1% | 12 | $41.56 | |
| 72040 | <1% | 41 | $41.20 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 351 | $31.55 |
| 96409 | <1% | 15 | $29.63 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 516 | $26.17 |
| 76536 | <1% | 72 | $24.63 | |
| 86301 | <1% | 16 | $24.42 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 14 | $21.34 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 13 | $11.70 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 240 | $11.55 |
| 84436 | <1% | 27 | $10.59 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 96 | $8.96 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 135 | $8.80 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 52 | $5.75 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 14 | $5.19 |
| 72110 | <1% | 99 | $4.77 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 103 | $4.65 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 321 | $0.91 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 34 | $0.50 |
| 0250R | 0% | 530 | $0.00 | |
| 89060 | 0% | 55 | $0.00 | |
| 87493 | 0% | 20 | $0.00 | |
| 71101 | 0% | 64 | $0.00 | |
| 70496 | 0% | 24 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 70 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 79 | $0.00 |
| 73552 | 0% | 37 | $0.00 | |
| 72128 | 0% | 38 | $0.00 | |
| 72072 | 0% | 37 | $0.00 | |
| 82803 | 0% | 12 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 15 | $0.00 |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | 0% | 16 | $0.00 |
| 0370 | 0% | 13 | $0.00 | |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | 0% | 85 | $0.00 |
| 84153 | 0% | 14 | $0.00 | |
| 83921 | 0% | 12 | $0.00 | |
| 86880 | 0% | 14 | $0.00 | |
| 77470 | 0% | 12 | $0.00 | |
| 94729 | 0% | 58 | $0.00 | |
| 94060 | 0% | 39 | $0.00 | |
| J9206 | Injection, irinotecan, 20 mg | 0% | 34 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 21 | $0.00 |
| 76999 | 0% | 12 | $0.00 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | 0% | 30 | $0.00 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 0% | 25 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 62 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 20 | $0.00 |
| 94726 | 0% | 29 | $0.00 | |
| 92611 | 0% | 13 | $0.00 | |
| 87653 | 0% | 13 | $0.00 | |
| 0510 | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWAGONER, CRAIG (CEO)
| Provider | Location | Paid |
|---|---|---|
| Fresno Community Hospital and Medical Center | Fresno, CA | $37.97M |
| Fresno Community Hospital and Medical Center | Fresno, CA | $6.83M |
| Fresno Community Hospital and Medical Center | Fresno, CA | $5.44M |
| Fresno Community Hospital and Medical Center | Fresno, CA | $3.41M |
| Fresno Community Hospital and Medical Center | Fresno, CA | $47K |
| Fresno Community Hospital and Medical Center | Fresno, CA | $45K |
| Clovis Community Medical Center | Clovis, CA | $12K |
| Fresno Community Hospital and Medical Center | Clovis, CA | $12K |
| Fresno Community Hospital and Medical Center | Fresno, CA | $10K |
| Fresno Community Hospital and Medical Center | Fresno, CA | $59.44 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.